CAGE1 and neoplasm: Interestingly, hCT3-1 CAR T cells demonstrated the highest antitumor efficacy compared to CT3 and the other hCT3 CAR T cells, with 33% (2 out of 6) of mice experiencing 100% tumor regression by week 3 post infusion.